International Pompe Association

You are here: Home News European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the European Commission has approved the production of Myozyme® (alglucosidase alfa) at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. The product will be made commercially available immediately. Myozyme is the only approved treatment for Pompe disease, a progressively debilitating and often fatal inherited disorder.

“This approval is important because it ensures that we can supply Myozyme to all patients in Europe who need treatment,” said Genzyme Senior Vice President Geoff McDonough. “We are grateful to all of the European authorities for their swift action on our application, and to the patients and physicians globally who helped us to conserve product supply over the past two months.”

Please Click Here To Read Full Press Release (PDF, 20 kB).